How CVS Health Corp. Makes Money

And Aetna's insurance operations posted a staggering underwriting loss in 2024, forcing the company to take multi-billion-dollar charges and prompting the ouster of CEO Karen Lynch in October 2024, replaced by David Joyner, a longtime CVS Health executive and Caremark veteran. Despite its massive scale, CVS faces significant near-term challenges including compressed pharmacy reimbursement rates, Aetna underwriting losses that contributed to a leadership change in late 2024, growing competitive pressure from Amazon and other digital health entrants, and mounting scrutiny of pharmacy benefit manager pricing practices from Congress and state legislatures. Revenue here comes from two primary sources: pharmacy dispensing (filling prescriptions in exchange for reimbursement from insurance plans and government programs, plus patient copays) and front-end retail sales (over-the-counter medications, personal care products, seasonal merchandise, and convenience goods). Here's why: Caremark earns revenue through administrative fees charged to plan sponsors, spread pricing (the difference between what it charges a plan sponsor for a drug and what it pays the dispensing pharmacy), and rebates negotiated with pharmaceutical manufacturers that may or may not be fully passed through to plan sponsors depending on contract terms. Yet size alone has never guaranteed profitability or competitive durability in healthcare — a sector where regulatory complexity, clinical quality requirements, and government pricing power create pattern that resist the straightforward application of retail or financial services business logic. Then, competition came primarily from Walgreens, Rite Aid, and independent pharmacies — traditional brick-and-mortar rivals competing on store count, location quality, and prescription pricing. The company took multi-billion-dollar charges related to Aetna and ultimately reported adjusted operating income that fell far short of analyst expectations. Congress has held multiple hearings examining PBM practices, and several states have passed laws restricting spread pricing, requiring rebate pass-through, or mandating greater PBM transparency. CVS developed a reputation for competitive pricing on over-the-counter health products and built the store format — accessible, well-lit, organized around health and personal care categories — that would remain largely recognizable for the next half-century. Aetna's Medicare Advantage business posted a staggering underwriting loss in 2024, forcing multi-billion-dollar charges. When medical cost trends — driven by post-pandemic use recovery and inflationary healthcare costs — ran significantly above premium assumptions, Aetna took multi-billion-dollar charges that erased operating income from the insurance segment. The PBM business faces regulatory scrutiny over spread pricing — the practice of charging health plan sponsors more for a drug than the PBM pays the pharmacy, pocketing the difference.

By 2024, more than 90 percent of Americans lived within ten miles of a CVS Pharmacy, a geographic density that took six decades of real estate investment to build. That growth reflects the Aetna integration layering insurance premiums onto the pharmacy revenue base, and the Caremark PBM processing a growing volume of specialty pharmacy claims. Congressional investigations and state Medicaid audits have intensified. The stock, which once traded above $100 per share, fell below $50 by mid-2024 as investors lost confidence in the integration thesis. The question facing CVS Health in 2025 is not whether it matters — it plainly does — but whether it can translate that scale into sustainable profitability, restore investor confidence, and execute a healthcare integration strategy that its rivals have so far been unable to replicate. The Pharmacy & Consumer Wellness segment is the company's retail and mail-order pharmacy operation, encompassing the branded CVS Pharmacy storefronts, the MinuteClinic walk-in clinic network inside CVS locations, and the growing HealthHUB store format. Caremark also operates specialty pharmacy services for high-cost complex medications, a segment of rapidly growing importance as biologic and gene therapy drugs become more prevalent. The fourth pillar is the company's expanding primary care footprint through Oak Street Health, acquired in May 2023 for approximately $10.6 billion. Oak Street had approximately 188 centers at time of acquisition and has continued expanding under CVS ownership. Surprisingly, Financially, the segment is early-stage relative to CVS's other businesses, still investing heavily in center openings, but strategically represents a crucial link in CVS's integrated care thesis: if CVS can manage a patient's insurance coverage through Aetna, fill their prescriptions through Caremark and CVS Pharmacy, and provide their primary care through Oak Street, the company captures healthcare dollar from multiple angles while theoretically improving care coordination and reducing total medical costs. What is certain is that the model requires immense capital, operational complexity spanning multiple regulated industries, and a management team capable of simultaneously running a retail chain, an insurance company, a PBM, and a clinical care network — a challenge that has proved more demanding than investors initially anticipated when the Aetna deal closed in 2018. CVS assembled its integrated stack through three large acquisitions in roughly seven years, each at peak valuations, and has struggled to extract the expected operational efficiencies at the pace investors anticipated. The competitive challenge, in this sense, is not merely external — it is internal, a question of whether CVS can manage a portfolio of businesses that span retail, insurance, technology, and clinical care with sufficient operational discipline to generate the returns that justify the capital invested. Americans are accustomed to walking into CVS for healthcare needs across a broad spectrum, from picking up antibiotics to getting a COVID booster, and that habitual engagement is a valuable asset in a sector where consumer trust is a prerequisite for clinical relationship-building. CVS Health's growth strategy under CEO David Joyner centers on three interrelated priorities that represent a course correction from the acquisition-led expansion of the Lynch era toward more disciplined organic growth and operational integration. Joyner has emphasized building care management programs that connect Aetna members with Oak Street primary care, CVS pharmacists, and Caremark specialty pharmacy in coordinated pathways. The third priority is expanding digital health and pharmacy capabilities to compete with Amazon and other digital-first entrants. This includes investment in CVS's mobile app and digital prescription management, expansion of same-day and next-day delivery options, and development of digital chronic disease management programs that extend the clinical relationship beyond the physical store visit. These investments are growth-oriented but also defensive, aimed at retaining customers who might otherwise migrate to pure-play digital pharmacy alternatives. Under CEO David Joyner, appointed in October 2024, CVS has signaled a renewed focus on operational execution over headline-grabbing acquisitions. Oak Street Health's expansion represents a long-term growth vector with genuine strategic logic. If CVS can grow Oak Street to 300-plus centers while maintaining its quality metrics and managing per-center economics, this business could become a meaningful earnings contributor by 2027-2028. The problem is, the story of CVS Health begins not in a hospital or a pharmaceutical laboratory but in a shopping mall — specifically, in the growing consumer shopping culture of early 1960s New England, where three entrepreneurs saw an opportunity to bring a new kind of value-oriented retail concept to health and beauty shoppers. Consumer Value Store — CVS — was designed to compete in the health, beauty, and personal care product space, differentiating itself from drugstores through a focus on product value and selection rather than the full-service pharmacy model that anchored traditional apothecaries and chain drugstores of the era. It was not until the 1970s that CVS expanded into prescription pharmacy services, adding pharmacists and dispensing counters as the company recognized that full-service pharmacy was essential to competing for the health-oriented shopper who was increasingly becoming the core CVS customer. Growth through the late 1960s and 1970s was organic, driven by store openings primarily in the northeastern United States. The far-reaching decade for CVS's physical growth was the 1980s and 1990s, when the company pursued an aggressive acquisition strategy that expanded its geographic reach from a regional New England chain to a national drugstore powerhouse. The 1998 acquisition of Arbor Drugs in Michigan and the 1999 acquisition of Soma.com's online pharmacy operations continued the growth cadence. By the turn of the millennium, CVS had grown into one of America's largest drugstore chains by store count and pharmacy prescription volume. But the growth trajectory that had defined the company's first four decades — open stores, acquire chains, repeat — was approaching its natural limits. Over the following decades, the company expanded aggressively through organic openings and acquisitions — Peoples Drug in 1990, Revco Drug Stores in 1997, Arbor Drugs in 1998.